【摘要】：目的探討miRNA-145在前列腺癌中的表達(dá)及其與臨床病理參數(shù)、預(yù)后的關(guān)系。方法前列腺癌患者120例為研究組,良性前列腺增生患者120例為對照組,通過免疫組織化學(xué)方法檢測兩組miRNA-145的表達(dá),分析miRNA-145的表達(dá)與研究組臨床參數(shù)及預(yù)后的關(guān)系。結(jié)果研究組miRNA-145的陽性表達(dá)率較對照組降低(P0.05),miRNA-145的表達(dá)與患者年齡、臨床分期、精囊浸潤無關(guān)(P0.05);而與前列腺特異抗原(PSA)、是否有淋巴結(jié)轉(zhuǎn)移、Gleason評分有關(guān)(P0.05)。miRNA-145陽性表達(dá)患者的無進(jìn)展生存率較miRNA-145陰性表達(dá)患者升高(P0.05)。結(jié)論miRNA-145在前列腺癌組織中表達(dá)下調(diào),其表達(dá)與前列腺癌組織的浸潤、轉(zhuǎn)移及預(yù)后有關(guān),這顯示miRNA-145可以作為一種新的分子靶點(diǎn)用于前列腺癌治療及預(yù)后評估。
[Abstract]:Objective to investigate the expression of miRNA-145 in prostate cancer and its relationship with clinicopathologic parameters and prognosis. Methods 120 patients with prostate cancer and 120 patients with benign prostatic hyperplasia as control group were studied. The expression of miRNA-145 was detected by immunohistochemistry, and the relationship between the expression of miRNA-145 and the clinical parameters and prognosis of the study group was analyzed. Results the positive expression rate of miRNA-145 in the study group was lower than that in the control group (P0.05). The expression of miRNA-145 was not related to the patient's age, clinical stage and seminal vesicle infiltration (P0.05). However, the Gleason score was related to whether the prostate specific antigen (PSA),) had lymph node metastasis or not (P0.05). The progression-free survival rate of the patients with positive miRNA-145 expression was higher than that of the patients with miRNA-145 negative expression (P0.05). Conclusion the expression of miRNA-145 is down-regulated in prostate cancer tissues, and its expression is related to the invasion, metastasis and prognosis of prostate cancer, which suggests that miRNA-145 can be used as a new molecular target for the treatment and prognosis evaluation of prostate cancer.
【作者單位】： 華中科技大學(xué)同濟(jì)醫(yī)學(xué)院附屬武漢中心醫(yī)院泌尿外科;
【分類號】：R737.25
，

本文編號：2412437